ANAB on XNAS, Health Care, AnaptysBio, Inc., job postings
Measures activity, not value. Not investment advice.
Latest quarter revenue fell 60% to $30.3M while insiders bought $17.2M and short interest is 17%.
WatchLast 12 months revenue still rose 13% to $191.6M
GoodInstitutional holders rose 7.6% to 226 filers from 210
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
expected around 8 Jan 2027 (an estimate: a year ago it reported on 9 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $30.3M, net income $3.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $183.9M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$30.3M
$3.9M
30 Jun 2026
$27.5M
$183.9M
31 Mar 2026
$25.6M
-$52.9M
31 Dec 2025
$108.2M
$49.6M
30 Sep 2025
$76.3M
$15.1M
30 Jun 2025
$22.3M
-$38.6M
31 Mar 2025
$27.8M
-$39.3M
31 Dec 2024
$43.1M
-$21.8M
30 Sep 2024
$30.0M
-$32.9M
30 Jun 2024
$11.0M
-$46.7M
31 Mar 2024
$7.2M
-$43.9M
31 Dec 2023
$9.0M
-$42.2M
30 Sep 2023
$3.3M
-$37.3M
30 Jun 2023
$3.5M
-$39.8M
31 Mar 2023
$1.4M
-$44.3M
31 Dec 2022
–
-$26.4M
30 Sep 2022
$1.3M
-$33.5M
30 Jun 2022
$1.2M
-$32.6M
31 Mar 2022
$970K
-$36.3M
31 Dec 2021
–
-$32.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$191.6M
$169.5M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+13%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$184.5M
-$84.6M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
8.2%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
96.3%
-49.9%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$145.3M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$153.0M
$249.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$153.0M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.70
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
7.5
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
7.2
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
6.4
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
66.6
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-60%
$30.3M vs $76.3M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$17.0M
bought $17.2M, sold $249K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+7.6%
226 13F filers vs 210
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
30.8M shares held by 13F filers (30 Sep 2026) of 29.7M outstanding (9 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
17%
5.1M shares sold short (30 Oct 2026) of 29.7M outstanding (9 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.8
5.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-6.3%
5.4M shares sold short in the report before, 5.1M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
54%
54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
21
21 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
21×
21 articles in the last 7 days; its usual week has 1.
Price $46.63 on 20 Nov 2026, +24% over 12 months (12-month range $37.66 to $70.22)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $7.5M in the last 12 months (the 12 months before: -$155K).Revenue per quarter. Revenue $30.3M in the latest quarter, -60% on a year earlier.Capital spending per quarter. Capital spending $17K in the latest quarter, -51% on a year earlier.Institutional holders (13F filers). 226 13F filers reported holding it in the latest 13F quarter, +44% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2022: $970K, -91% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $1.2M, -96% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $1.3M, -94% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Mar 2023: $1.4M, +42% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $3.5M, +185% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $3.3M, +157% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $9.0M; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $7.2M, +422% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $11.0M, +217% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $30.0M, +805% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $43.1M, +379% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $27.8M, +287% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $22.3M, +103% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $76.3M, +154% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $108.2M, +151% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $25.6M, -8.0% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $27.5M, +23% on a year earlier; public on 22 Sep 2026
Quarter ended 30 Sep 2026: $30.3M, -60% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $55K, -83% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $78K, -91% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $50K, -71% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $175K; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $175K, +218% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $190K, +144% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $162K, +224% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $280K, +60% on a year earlier; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $27K, -85% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $33K, -83% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $35K, -78% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $263K, -6.1% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $35K, +30% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $39K, +18% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $12K, -66% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $17K, -51% on a year earlier; public on 13 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 128; public on 14 Feb 2022
31 Mar 2022 report: 128; public on 16 May 2022
30 Jun 2022 report: 119; public on 15 Aug 2022
30 Sep 2022 report: 108; public on 14 Nov 2022
31 Dec 2022 report: 110; public on 14 Feb 2023
31 Mar 2023 report: 108; public on 15 May 2023
30 Jun 2023 report: 109; public on 14 Aug 2023
30 Sep 2023 report: 110; public on 14 Nov 2023
31 Dec 2023 report: 113; public on 14 Feb 2024
31 Mar 2024 report: 128; public on 15 May 2024
30 Jun 2024 report: 126; public on 14 Aug 2024
30 Sep 2024 report: 155; public on 14 Nov 2024
31 Dec 2024 report: 133; public on 14 Feb 2025
31 Mar 2025 report: 152; public on 15 May 2025
30 Jun 2025 report: 142; public on 14 Aug 2025
30 Sep 2025 report: 157; public on 14 Nov 2025
31 Dec 2025 report: 174; public on 17 Feb 2026
31 Mar 2026 report: 199; public on 15 May 2026
30 Jun 2026 report: 210; public on 14 Aug 2026
30 Sep 2026 report: 226; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $17.2M (18 Nov 2026), higher than 98% of its own history.
In 12 months: 3 major agreements, 3 director or officer changes, 1 agreement ended, 1 completed deal. Results releases and routine reports are left out.
Two or more unrelated kinds of records unusual within 30 days
19 Nov 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
AnaptysBio(ANAB): reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year; it also saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year; and it had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year. Three unrelated kinds of activity within 35 days.
Financials: Quarterly revenue change, became public on 12 Nov 2024
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
Short interest and volume: Short interest spike, became public on 11 Dec 2024
The quarter ended 30 Sep 2024 against the 8 quarters before it.
this quarterearliernormal: $3.4MSee the evidence (3 changes)
Financials: Quarterly revenue change became public on 12 Nov 2024
AnaptysBio reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year.
This period
$30.0M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$3.4M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+8.4
Same quarter last year
$3.3M
History used
3,105 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $3.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
AnaptysBio saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year.
This period
32 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
12.5
Typical spread (median absolute deviation)
2
How far from its usual level
+6.5
Same quarter last year
10
History used
2,740 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 12.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Dec 2024
AnaptysBio had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year.
This period
7.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
4.7M
Typical spread (median absolute deviation)
436K
How far from its usual level
+3.7
Same report last year
5.0M
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 4.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
17 Mar 2020confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
AnaptysBio(ANAB): saw 34 13F filers open a new position in the quarter ended 31 Dec 2019, 2.0× the same quarter last year; it also had 6.0M shares sold short in the 13 Mar 2020 report, 1.8× the same report last year; and it reported revenue of $15.0M for the quarter ended 31 Mar 2020, against none in the same quarter last year. Three unrelated kinds of activity within 84 days.
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2020
Short interest and volume: Short interest spike, became public on 11 Mar 2020
Short interest and volume: Short interest spike, became public on 25 Mar 2020
Short interest and volume: Short interest spike, became public on 10 Apr 2020
Short interest and volume: Short interest spike, became public on 25 Apr 2020
Financials: Quarterly revenue change, became public on 12 May 2020
The quarter ended 31 Dec 2019 against the 8 quarters before it.
this quarterearliernormal: 21See the evidence (6 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2020
AnaptysBio saw 34 13F filers open a new position in the quarter ended 31 Dec 2019, 2.0× the same quarter last year.
This period
34 (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
21
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.5
Same quarter last year
17
History used
1,005 days
the quarter ended 31 Dec 20198 earlier quartersnormal: 21
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Mar 2020
AnaptysBio had 5.6M shares sold short in the 28 Feb 2020 report, 1.8× the same report last year.
This period
5.6M (the 28 Feb 2020 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
317K
How far from its usual level
+4.2
Same report last year
3.2M
History used
791 days
the 28 Feb 2020 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2020
AnaptysBio had 6.0M shares sold short in the 13 Mar 2020 report, 1.8× the same report last year.
This period
6.0M (the 13 Mar 2020 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
281K
How far from its usual level
+5.5
Same report last year
3.4M
History used
805 days
the 13 Mar 2020 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2020
AnaptysBio had 6.2M shares sold short in the 31 Mar 2020 report, 1.8× the same report last year.
This period
6.2M (the 31 Mar 2020 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
360K
How far from its usual level
+4.6
Same report last year
3.4M
History used
823 days
the 31 Mar 2020 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2020
AnaptysBio had 6.2M shares sold short in the 15 Apr 2020 report, 1.7× the same report last year.
This period
6.2M (the 15 Apr 2020 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
384K
How far from its usual level
+4.2
Same report last year
3.7M
History used
838 days
the 15 Apr 2020 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 12 May 2020
AnaptysBio reported revenue of $15.0M for the quarter ended 31 Mar 2020, against none in the same quarter last year.
This period
$15.0M (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+15.0
Same quarter last year
$0
History used
1,461 days
the quarter ended 31 Mar 20208 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
reported revenue of $108.2M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year.
Same quarter last year: $43.1M; its normal quarter is $25.0M.
See the evidence
This period
$108.2M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$25.0M
Typical spread (median absolute deviation)
$15.0M
How far from its usual level
+3.7
Same quarter last year
$43.1M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $25.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $76.3M for the quarter ended 30 Sep 2025, 2.5× the same quarter last year.
Same quarter last year: $30.0M; its normal quarter is $16.6M.
See the evidence
This period
$76.3M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$16.6M
Typical spread (median absolute deviation)
$10.3M
How far from its usual level
+3.9
Same quarter last year
$30.0M
History used
3,470 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $16.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year.
Same quarter last year: 23; its normal quarter is 14.5.
See the evidence
This period
43 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
14.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+5.5
Same quarter last year
23
History used
2,922 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 14.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $43.1M for the quarter ended 31 Dec 2024, 4.8× the same quarter last year.
Same quarter last year: $9.0M; its normal quarter is $5.3M.
See the evidence
This period
$43.1M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$5.3M
Typical spread (median absolute deviation)
$3.8M
How far from its usual level
+6.7
Same quarter last year
$9.0M
History used
3,197 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $5.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year.
Same report last year: 5.0M; its normal report is 4.7M.
See the evidence
This period
7.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
4.7M
Typical spread (median absolute deviation)
436K
How far from its usual level
+3.7
Same report last year
5.0M
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 4.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year; it also saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year; and it had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year. Three unrelated kinds of activity within 35 days.
See the evidence (3 changes)
Financials: Quarterly revenue change became public on 12 Nov 2024
AnaptysBio reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year.
This period
$30.0M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$3.4M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+8.4
Same quarter last year
$3.3M
History used
3,105 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $3.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
AnaptysBio saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year.
This period
32 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
12.5
Typical spread (median absolute deviation)
2
How far from its usual level
+6.5
Same quarter last year
10
History used
2,740 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 12.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Dec 2024
AnaptysBio had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year.
This period
7.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
4.7M
Typical spread (median absolute deviation)
436K
How far from its usual level
+3.7
Same report last year
5.0M
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 4.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2024Institutional holdings change
saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year.
Same quarter last year: 10; its normal quarter is 12.5.
See the evidence
This period
32 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
12.5
Typical spread (median absolute deviation)
2
How far from its usual level
+6.5
Same quarter last year
10
History used
2,740 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 12.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year.
Same quarter last year: $3.3M; its normal quarter is $3.4M.
See the evidence
This period
$30.0M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$3.4M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+8.4
Same quarter last year
$3.3M
History used
3,105 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $3.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $11.0M for the quarter ended 30 Jun 2024, 3.2× the same quarter last year.
Same quarter last year: $3.5M; its normal quarter is $2.3M.
See the evidence
This period
$11.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$2.3M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+5.2
Same quarter last year
$3.5M
History used
3,013 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $2.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 23 13F filers open a new position in the quarter ended 31 Mar 2024, 1.8× the same quarter last year.
Same quarter last year: 13; its normal quarter is 12.5.
See the evidence
This period
23 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
12.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+3.5
Same quarter last year
13
History used
2,557 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 12.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 5.5M shares sold short in the 14 Oct 2022 report, 2.2× the same report last year.
Same report last year: 2.5M; its normal report is 2.7M.
See the evidence
This period
5.5M (the 14 Oct 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
390K
How far from its usual level
+4.9
Same report last year
2.5M
History used
1,750 days
the 14 Oct 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.6M shares sold short in the 30 Sep 2022 report, 2.2× the same report last year.
Same report last year: 2.6M; its normal report is 2.7M.
See the evidence
This period
5.6M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
379K
How far from its usual level
+5.2
Same report last year
2.6M
History used
1,736 days
the 30 Sep 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.4M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.
Same report last year: 2.8M; its normal report is 2.7M.
See the evidence
This period
5.4M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
360K
How far from its usual level
+5.1
Same report last year
2.8M
History used
1,721 days
the 15 Sep 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.2M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.
Same report last year: 2.9M; its normal report is 2.7M.
See the evidence
This period
5.2M (the 31 Aug 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
340K
How far from its usual level
+5.0
Same report last year
2.9M
History used
1,706 days
the 31 Aug 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 15 Aug 2022 report, 1.5× the same report last year.
Same report last year: 2.9M; its normal report is 2.7M.
See the evidence
This period
4.4M (the 15 Aug 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
321K
How far from its usual level
+3.6
Same report last year
2.9M
History used
1,690 days
the 15 Aug 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.5M shares sold short in the 29 Jul 2022 report, 1.5× the same report last year.
Same report last year: 2.9M; its normal report is 2.7M.
See the evidence
This period
4.5M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
321K
How far from its usual level
+3.8
Same report last year
2.9M
History used
1,673 days
the 29 Jul 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $30.0M for the quarter ended 30 Jun 2021, against none in the same quarter last year.
See the evidence
This period
$30.0M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$4.0M
Typical spread (median absolute deviation)
$4.0M
How far from its usual level
+4.4
Same quarter last year
$0
History used
1,917 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $4.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 85 entries; narrow the window or the kind of data to see older ones.
Not listed: 179 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001370053
Ticker
ANAB
Domain
anaptysbio.com
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Name
AnaptysBio, Inc., ANAPTYS BIOSCIENCES INC
Uei
MSWSM1BGJNZ6
SEC Form 13F institutional holdings351 data points31 Mar 2017 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)139 records16 Feb 2016 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)575 data points31 Dec 2014 to 9 Nov 2026
SEC Form 4 insider transactions88 records, 236 data points31 Jan 2017 to 18 Nov 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards1 record, 21 data points17 Jun 2010 to 19 Mar 2015